Bristol surgeon one of first to conduct 'game changing' Parkinson's treatment

Bristol Post

Center

Factuality

Ownership

Bristol surgeon one of first to conduct 'game changing' Parkinson's treatment

Implants in the brain that adapt are a 'critical advancement in how we treat Parkinson’s disease'

AT5

Factuality

Ownership

The Amsterdam UMC was the first in the world to treat a patient with a new method for Parkinson's. A 47-year-old man underwent the treatment that was 'tailor-made' for him by means of a new form of brain stimulation. The use of brain stimulation for Parkinson's disease is not new, it has been done for about thirty years. In this method, electrodes are placed in the brain that continuously emit a pulse, which reduces the symptoms of the movement …

rtl.nl

Factuality

Ownership

Yesterday, the Amsterdam UMC was the first in the world to treat a patient with a new, 'custom-made' Parkinson's treatment method. This was done with adaptive brain stimulation, in which electrodes send pulses to the brain when the patient's brain itself asks for it. 'A very special day', says Martijn Beudel, neurologist at the Amsterdam UMC.

rd.nl

Factuality

Ownership

A 47-year-old man was the first in the world to be treated outside of a study setting with a new technique for the symptoms of Parkinson's disease, Amsterdam UMC reports. This technique is called Adaptive DBS (aDBS) and delivers so-called pulses (shocks) to the brain when necessary.

Med-Tech Innovation | Latest news for the medical device industry

Factuality

Ownership

Medtronic achieves CE Mark approval for BrainSense Adaptive deep brain stimulation and Electrode Identifier

Medtronic has announced CE Mark approval in the European Union and the United Kingdom for its BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI).

Endpoints News

Factuality

Ownership

Bayer’s BlueRock now plans to bring Parkinson’s cell therapy straight to Phase 3 trial

Bayer's experimental Parkinson’s disease therapy made from stem cells will soon enter late-stage studies, marking a key test for regenerative medicine in neurologic conditions. The therapy, known as bemdaneprocel, is being developed by BlueRock Therapeutics ...